1.25
-8.09%
Close of 20 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
Price performance
Chart by TradingView, with its own licensed prices
- Market value
- $75.9m
- Last close × shares
- Volume
- 523.9k
- Shares, 20 Nov 2026
About TuHURA Biosciences
From its filings with the US Securities and Exchange Commission
TuHURA Biosciences is based in Tampa, Florida and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker HURA. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $30.1m. At that date it held total assets of $27.4m and shareholders' equity of $20.9m.
We are a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies.
Our proprietary Immune FxTM technology platform, or IFx, is an innate immune agonist technology designed to “trick” the body’s immune system to attack tumor cells by making tumor cells look like bacteria. Our lead product candidate, IFx2.0, is an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. In June 2025, we initiated a single randomized placebo-controlled Phase 3 registration trial of administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for patients with advanced or metastatic Merkel cell carcinoma who are checkpoint inhibitor naïve utilizing the FDA’s accelerated approval pathway.
In addition to our IFx technology platform, in June 2025 we acquired the rights to TBS-2025, a novel VISTA-inhibiting monoclonal antibody formerly known as KVA1213, through our acquisition of Kineta, Inc. (“Kineta”) on June 30, 2025. VISTA (otherwise referred to as V-domain Ig suppressor of T cell activation) is an immune checkpoint highly expressed on myeloid cells that is believed to be a strong driver of immunosuppression in the tumor microenvironment and is believed to be a primary mechanism by which leukemic blasts escape immune recognition contributing to low response rates and high rates of recurrence in acute myeloid leukemia, or AML.
Quoted from its 10-K, filed 31 Mar 2026. Read the filing on SEC.gov ↗
Latest on TuHURA Biosciences
Our reporting
- TuHURA Biosciences falls 8.09% in Friday's session
- TuHURA Biosciences falls 2.14% in Wednesday's session
- TuHURA Biosciences rises 5.26% in Tuesday's session
- TuHURA Biosciences falls 4.32% in Monday's session
- TuHURA Biosciences falls 4.14% in Friday's session
- TuHURA Biosciences falls 4.61% in Thursday's session
Next results
Due on 30 Mar 2027. Analysts expect earnings of -0.05 a share.
Other Health Care listings
Scenario calculator
Try your own numbers. This is arithmetic, not a forecast.
Gain or loss
Return
Leaves out fees, taxes and financing.
Frequently asked questions
What is TuHURA Biosciences's ticker?
TuHURA Biosciences trades as HURA on its US listing, under ISIN US8989201038.
What was TuHURA Biosciences's last closing price?
1.25 on 20 Nov 2026. The figure is in USD and is never converted.
When does TuHURA Biosciences next report results?
Results are expected on 13 Nov 2026, according to our data supplier.
Sources and methodology
- Chart
- TradingView
- Close and company data
- SEC filings and our data supplier
- News
- Our reporting
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.